1. Home
  2. CIK vs CGEN Comparison

CIK vs CGEN Comparison

Compare CIK & CGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Credit Suisse Asset Management Income Fund Inc.

CIK

Credit Suisse Asset Management Income Fund Inc.

HOLD

Current Price

$2.73

Market Cap

156.2M

Sector

Finance

ML Signal

HOLD

Logo Compugen Ltd.

CGEN

Compugen Ltd.

HOLD

Current Price

$1.77

Market Cap

148.7M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
CIK
CGEN
Founded
N/A
1993
Country
United States
Israel
Employees
N/A
N/A
Industry
Finance/Investors Services
Biotechnology: Biological Products (No Diagnostic Substances)
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
156.2M
148.7M
IPO Year
1995
2001

Fundamental Metrics

Financial Performance
Metric
CIK
CGEN
Price
$2.73
$1.77
Analyst Decision
Strong Buy
Analyst Count
0
1
Target Price
N/A
$4.00
AVG Volume (30 Days)
382.0K
203.5K
Earning Date
01-01-0001
01-01-0001
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
N/A
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
$164.92
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$2.56
$1.13
52 Week High
$3.01
$2.38

Technical Indicators

Market Signals
Indicator
CIK
CGEN
Relative Strength Index (RSI) 36.28 44.73
Support Level $2.74 $1.47
Resistance Level $3.00 $1.72
Average True Range (ATR) 0.03 0.09
MACD -0.01 -0.01
Stochastic Oscillator 22.18 45.87

Price Performance

Historical Comparison
CIK
CGEN

About CIK Credit Suisse Asset Management Income Fund Inc.

Credit Suisse Asset Mgmt Income Fund Inc is a closed-end management investment company. The investment objective of the fund is to provide current income consistent with the preservation of capital. Credit Suisse serves as an investment adviser for the fund. Asset Management offers a wide range of investment products and functions across asset classes and investment styles. The division manages various regional portfolios, mutual funds, and other investment vehicles for governments, institutions, corporations and individuals.

About CGEN Compugen Ltd.

Compugen Ltd is a clinical-stage therapeutic discovery and development company utilizing its broadly applicable predictive computational discovery capabilities to identify novel drug targets and new biological pathways to develop therapeutics in the field of cancer immunotherapy. Its immuno-oncology pipeline consists of four clinical-stage programs, targeting immune checkpoints the company discovered computationally, COM701, COM902 and bapotulimab. The company's therapeutic pipeline of early-stage immuno-oncology programs consists of programs aiming to address various mechanisms of immune resistance, including myeloid targets.

Share on Social Networks: